BVS

Bioventus Inc

10.48

Jul 02 • 04:00PM ET +0.63 (6.40%)

Healthcare Medical Devices USA Small NASD

Peers: CNMD IART SYK BSX EW MDT ABT TFX BDX BAX

| Held by: IWM AVUV VTI IWO VXF FESM SCHA DFMC DFAS VTWO

Scroll to Statements

Index	RUT
Market Cap	875.44M
Enterprise Value	1.17B
Income	28.48M
Sales	576.30M
Book/sh	2.79
Cash/sh	0.43
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	930
IPO	Feb 11, 2021

P/E	25.42
Forward P/E	11.56
PEG	0.71
P/S	1.52
P/B	3.75
P/C	24.42
P/FCF	8.76
EV/EBITDA	10.90
EV/Sales	2.04
Quick Ratio	1.13
Current Ratio	1.69
Debt/Eq	1.53
LT Debt/Eq	1.41
Option/Short	Yes / Yes

EPS (ttm)	0.41
EPS next Y	0.91
EPS next Q	0.22
EPS this Y	14.17%
EPS next Y	16.77%
EPS next 5Y	16.31%
EPS past 3/5Y	- 33.74%
Sales past 3/5Y	3.52% 12.08%
EPS Y/Y TTM	186.74%
Sales Y/Y TTM	1.52%
EPS Q/Q	211.25%
Sales Q/Q	6.63%
Earnings	May 06 BMO
EPS/Sales Surpr.	117.71% 1.67%

Insider Own	31.08%
Insider Trans	-0.05%
Inst Own	56.26%
Inst Trans	0.85%
ROA	4.24%
ROE	16.90%
ROIC	6.27%
Gross Margin	67.78%
Oper. Margin	10.64%
Profit Margin	4.94%
SMA20	14.32%
SMA50	9.56%
SMA200	26.32%
Trades

Shs Outstand	67.64M
Shs Float	46.69M
Short Float	4.13%
Short Ratio	3.24
Short Interest	1.93M
52W High	11.25 -6.84%
52W Low	5.81 80.38%
Volatility	5.41% 4.55%
ATR (14)	0.47
RSI (14)	66.50
Beta	0.67
Rel Volume	1.18
Avg Volume	595.17K
Volume	699,444

Perf Week	7.71%
Perf Month	29.22%
Perf Quarter	14.54%
Perf Half Y	40.67%
Perf YTD	40.86%
Perf Year	52.99%
Perf 3Y	262.63%
Perf 5Y	-36.52%
Perf 10Y	-
Recom	1.00
Target Price	14.80
Prev Close	9.85
Price	10.48
Change	6.40%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-26	Initiated	CJS Securities	Market Outperform	$14
Feb-09-26	Initiated	Barrington Research	Outperform	$13
Jul-07-25	Initiated	Cantor Fitzgerald	Overweight	$12
Dec-17-24	Upgrade	JP Morgan	Underweight → Neutral	$12 → $13
Dec-07-23	Upgrade	Canaccord Genuity	Hold → Buy	$7
Aug-09-23	Upgrade	Craig Hallum	Hold → Buy	$4 → $6
Nov-22-22	Downgrade	Craig Hallum	Buy → Hold
Nov-09-22	Downgrade	JP Morgan	Overweight → Underweight
Nov-09-22	Downgrade	Canaccord Genuity	Buy → Hold	$18 → $6
Mar-15-22	Initiated	Craig Hallum	Buy	$30
Nov-15-21	Resumed	Morgan Stanley	Overweight	$20
Nov-10-21	Resumed	JP Morgan	Overweight	$25
Jul-01-21	Downgrade	Goldman	Buy → Neutral	$20 → $19
Mar-08-21	Initiated	Morgan Stanley	Overweight	$18
Mar-08-21	Initiated	JP Morgan	Overweight	$17
Mar-08-21	Initiated	Goldman	Buy	$19
Mar-08-21	Initiated	Canaccord Genuity	Buy	$23

Show Previous Ratings

Today 12:24PM	Did Bioventus Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire)
Jun-02-26 09:00AM	The Body as Blueprint: A Recently Public Biotech Bets That Regrown Tissue Beats Replacement Parts (PR Newswire)
07:00AM	Bioventus to Present at the Goldman Sachs 47TH Annual Global Healthcare Conference (GlobeNewswire)
May-22-26 10:31AM	Regenerative Medicine's Newest Public Company Is Building Tissue, Not Replacing It (PR Newswire)
May-06-26 04:48PM	Bioventus Inc. Q1 2026 Earnings Call Summary (Moby)
07:44AM	Loading…
07:44AM	Bioventus: Q1 Earnings Snapshot (Associated Press)
07:30AM	Bioventus Reports First Quarter Financial Results (GlobeNewswire)
Apr-28-26 04:15PM	Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026 (GlobeNewswire)
Mar-05-26 06:47PM	Bioventus Q4 Earnings Call Highlights (MarketBeat) +7.44% -7.58%
04:02PM	Bioventus Inc (BVS) Q4 2025 Earnings Call Highlights: Strong Organic Growth and Strategic ... (GuruFocus.com)
12:33PM	Bioventus Inc. Q4 2025 Earnings Call Summary (Moby)
07:33AM	Bioventus: Q4 Earnings Snapshot (Associated Press Finance)
07:00AM	Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-24-26 04:15PM	Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026 (GlobeNewswire)
Jan-15-26 07:55PM	Bioventus Details Turnaround Plan, Four Growth Drivers at J.P. Morgan Conference (MarketBeat)
07:30AM	Loading…
Jan-06-26 07:30AM	Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-05-25 03:30PM	HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire) -6.96%
Nov-25-25 04:15PM	Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire) +5.13%
Nov-04-25 04:08PM	Bioventus Inc (BVS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com) +15.09%
07:44AM	Bioventus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Bioventus Reports Third Quarter Financial Results (GlobeNewswire)
Nov-03-25 08:02AM	What To Expect From Bioventus Inc (BVS) Q3 2025 Earnings (GuruFocus.com)
Oct-28-25 07:00AM	Bioventus to Report Third Quarter of Fiscal Year 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Oct-22-25 07:08PM	Halper Sadeh LLC Encourages Bioventus Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Sep-03-25 07:30AM	Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-13-25 12:08PM	Craig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PT (Insider Monkey)
Aug-07-25 04:15PM	Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference (GlobeNewswire)
Aug-06-25 08:55AM	Bioventus (BVS) Misses Q2 Earnings and Revenue Estimates (Zacks) +18.73%
07:52AM	Bioventus: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Bioventus Reports Second Quarter Financial Results (GlobeNewswire)
10:18AM	Loading…
Aug-05-25 10:18AM	What To Expect From Bioventus Inc (BVS) Q2 2025 Earnings (GuruFocus.com)
Aug-04-25 08:00AM	Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity (GlobeNewswire)
Jul-30-25 07:30AM	Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products (GlobeNewswire)
Jul-29-25 04:15PM	Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025 (GlobeNewswire)
Jul-16-25 09:39AM	Cantor Fitzgerald Initiates Coverage of Bioventus (BVS) with an Overweight Rating (Insider Monkey)
Jun-13-25 08:30AM	Do Options Traders Know Something About Bioventus Stock We Don't? (Zacks)
May-07-25 03:09AM	Bioventus Inc (BVS) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Divestitures (GuruFocus.com) +6.29%
01:21AM	Q1 2025 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents)
May-06-25 08:45AM	Bioventus (BVS) Q1 Earnings and Revenues Surpass Estimates (Zacks) -11.81%
07:50AM	Bioventus: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Bioventus Reports First Quarter Financial Results (GlobeNewswire)
May-05-25 10:10AM	Bioventus Inc (BVS) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Apr-28-25 08:00AM	Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025 (GlobeNewswire)
Apr-24-25 01:25AM	Artisan Sustainable Emerging Markets Fund Q1 2025 Commentary (Seeking Alpha)
Apr-17-25 08:21AM	4 Healthcare Stocks to Buy as the Sector Faces Government Heat (Zacks)
Apr-03-25 01:09PM	Ensign Group Invests in Growth With New Facility Acquisitions (Zacks)
Mar-31-25 09:55AM	Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Mar-28-25 11:06AM	Centene & HMHB Hawaii Expand Partnership for Maternal Care (Zacks)
Mar-17-25 12:00PM	Bioventus (BVS) Upgraded to Buy: Here's What You Should Know (Zacks)
Mar-12-25 03:08AM	Q4 2024 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) -6.76%
03:04AM	Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ... (GuruFocus.com)
Mar-11-25 08:45AM	Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates (Zacks) +23.29%
07:52AM	Bioventus: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-28-25 07:30AM	Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025 (GlobeNewswire)
Jan-07-25 08:00AM	Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-03-25 08:05AM	Bioventus completes divestiture of its Advanced Rehabilitation business (TipRanks)
Jan-02-25 08:00AM	Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners (GlobeNewswire)
Dec-23-24 09:40AM	Is Bioventus (BVS) Outperforming Other Medical Stocks This Year? (Zacks)
Dec-06-24 09:55AM	Wall Street Analysts Think Bioventus (BVS) Could Surge 26.03%: Read This Before Placing a Bet (Zacks)
Nov-06-24 02:43AM	Q3 2024 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents)
02:14AM	Bioventus Inc (BVS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... (GuruFocus.com)
Nov-05-24 08:45AM	Bioventus (BVS) Matches Q3 Earnings Estimates (Zacks) -16.27%
07:41AM	Bioventus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Bioventus Reports Third Quarter Financial Results (GlobeNewswire)
Nov-04-24 09:40AM	Are Medical Stocks Lagging Bioventus (BVS) This Year? (Zacks)
07:09AM	Bioventus Inc (BVS) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-29-24 07:30AM	Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024 (GlobeNewswire)
Oct-15-24 04:01PM	Solventum Stock Earns 81 RS Rating (Investor's Business Daily)
Oct-09-24 05:03PM	Bioventus Inc (BVS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Oct-01-24 09:00AM	Bioventus Announces Divestiture of its Advanced Rehabilitation Business to Accelmed Partners (GlobeNewswire)
Aug-29-24 07:09AM	Bull Of The Day: Bioventus (BVS) (Zacks)
Aug-07-24 04:15PM	Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference (GlobeNewswire) -7.79%
Aug-06-24 07:30AM	Bioventus Reports Second Quarter Financial Results (GlobeNewswire) +29.23%
Jul-30-24 07:30AM	Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jun-05-24 10:17AM	Here's Why You Should Consider Buying Bioventus (BVS) Stock (Zacks)
May-23-24 06:42AM	3 Stocks Under $10 With Mammoth Growth Prospects (InvestorPlace)
May-09-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +8.33%
May-08-24 12:28PM	Bioventus Inc. (NASDAQ:BVS) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:19AM	Bioventus Inc (BVS) Q1 2024 Earnings Call Transcript Highlights: Strong Start with Significant ... (GuruFocus.com)
May-07-24 11:41PM	Q1 2024 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) +28.00%
07:00AM	Bioventus Reports First Quarter Financial Results (GlobeNewswire)
Apr-29-24 07:30AM	Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024 (GlobeNewswire)
Mar-13-24 08:48AM	Bioventus Inc. (NASDAQ:BVS) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.54%
Mar-12-24 10:20PM	Q4 2023 Bioventus Inc Earnings Call (Thomson Reuters StreetEvents) +5.46%
09:11AM	Bioventus Inc (BVS) Reports Growth in Q4 Sales and Adjusted EBITDA, Provides Optimistic 2024 ... (GuruFocus.com)
07:30AM	Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-04-24 08:00AM	Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024 (GlobeNewswire)
Jan-18-24 04:15PM	Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility (GlobeNewswire)
Jan-12-24 04:15PM	Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole (GlobeNewswire)
Dec-19-23 04:30PM	Bioventus Names Robert Claypoole as President and Chief Executive Officer (GlobeNewswire)
Dec-06-23 08:00AM	Bioventus Agrees to Nationwide Contract with Aetna Medicare Advantage Plans for DUROLANE for Knee Osteoarthritis (GlobeNewswire)
Nov-27-23 01:33AM	Smith & Nephew inks $180M CartiHeal buyout, capitalizing on Bioventus turmoil to land knee implant (MedTech Dive)
Nov-12-23 09:02AM	Bioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 07:59AM	Bioventus Inc (BVS) Reports Q3 2023 Financial Results, Raises Full Year 2023 Financial Guidance (GuruFocus.com)
07:00AM	Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance (GlobeNewswire)
Oct-31-23 07:00AM	Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023 (GlobeNewswire) +5.37%
Oct-25-23 10:48AM	Bioventus (BVS) to Report Q3 Earnings: What's in the Cards? (Zacks)
Sep-28-23 07:43AM	3 Value Medical Stocks to Buy for Safety Amid Market Volatility (Zacks)
Sep-19-23 09:52PM	Bioventus to Present at the Cantor Global Healthcare Conference (GlobeNewswire)

Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.

PresidentMr. Robert E. Claypoole

Senior VP & CFOMr. Mark L. Singleton

Senior VPMr. Anthony D'Adamio J.D.

M.B.A.Mr. Mike Crowe B.S.

Vice President of Investor Relations & TreasurerMr. David Crawford

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bartholdson John A.	Director	Jun 02 '26	Option Exercise	0.00	32,282	0	111,902	Jun 04 05:06 PM
SUTTER MARTIN P	Director	Jun 02 '26	Option Exercise	0.00	32,282	0	117,523	Jun 04 04:48 PM
STALNECKER SUSAN M	Director	Jun 02 '26	Option Exercise	0.00	32,282	0	138,239	Jun 04 04:47 PM
NOHRA GUY P	Director	Jun 02 '26	Option Exercise	0.00	32,282	0	148,892	Jun 04 04:47 PM
NEELS GUIDO J	Director	Jun 02 '26	Option Exercise	0.00	32,282	0	117,523	Jun 04 04:47 PM
McMurry-Heath Michelle	Director	Jun 02 '26	Option Exercise	0.00	32,282	0	77,279	Jun 04 04:47 PM
Ladone Mary Kay	Director	Jun 02 '26	Option Exercise	0.00	32,282	0	111,263	Jun 04 04:46 PM
HAWKINS WILLIAM A	Director	Jun 02 '26	Option Exercise	0.00	39,789	0	297,640	Jun 04 04:46 PM
Cowdy Philip G.	Director	Jun 02 '26	Option Exercise	0.00	32,282	0	43,982	Jun 04 04:46 PM
Beyer Pat	Director	Jun 02 '26	Option Exercise	0.00	32,282	0	108,718	Jun 04 04:45 PM
Singleton Mark Leonard	SVP & CFO	Apr 10 '26	Option Exercise	0.00	13,000	0	182,981	Apr 14 06:18 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Apr 10 '26	Option Exercise	0.00	4,300	0	66,032	Apr 14 06:18 PM
D'Adamio Anthony	SVP & General Counsel	Apr 10 '26	Option Exercise	0.00	9,925	0	157,967	Apr 14 06:17 PM
Singleton Mark Leonard	SVP & CFO	Mar 20 '26	Option Exercise	0.00	18,625	0	178,072	Mar 24 04:59 PM
Singleton Mark Leonard	SVP & CFO	Mar 13 '26	Option Exercise	0.00	13,500	0	165,312	Mar 17 05:03 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Mar 13 '26	Option Exercise	0.00	6,955	0	63,253	Mar 17 05:02 PM
D'Adamio Anthony	SVP & General Counsel	Mar 13 '26	Option Exercise	0.00	17,636	0	151,844	Mar 17 05:01 PM
Claypoole Robert E	President and CEO	Mar 13 '26	Option Exercise	0.00	33,500	0	150,497	Mar 17 05:00 PM
McMurry-Heath Michelle	Director	Mar 11 '26	Sale	8.79	12,000	105,439	44,997	Mar 13 05:26 PM
McMurry-Heath Michelle	Director	Mar 11 '26	Proposed Sale	8.81	12,000	105,720		Mar 11 10:47 AM
Singleton Mark Leonard	SVP & CFO	Feb 15 '26	Option Exercise	0.00	20,153	0	161,241	Feb 18 06:30 PM
CHURCH KATRINA J	SVP & Chief Compliance Officer	Feb 15 '26	Option Exercise	0.00	4,375	0	59,932	Feb 18 06:29 PM
D'Adamio Anthony	SVP & General Counsel	Feb 15 '26	Option Exercise	0.00	12,980	0	144,396	Feb 18 06:28 PM
Claypoole Robert E	President and CEO	Jan 09 '26	Option Exercise	0.00	93,750	0	158,714	Jan 13 05:30 PM
NOHRA GUY P	Director	Dec 04 '25	Sale	7.57	10,000	75,658	116,610	Dec 08 05:02 PM
NOHRA GUY P	Director	Dec 04 '25	Proposed Sale	7.57	10,000	75,658		Dec 04 01:54 PM
McMurry-Heath Michelle	Director	Nov 07 '25	Sale	7.42	17,701	131,255	56,997	Nov 10 05:08 PM
McMurry-Heath Michelle	Director	Nov 07 '25	Proposed Sale	7.41	27,000	200,041		Nov 07 04:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

BVS

Bioventus Inc

Upgrade your Finviz experience